Use of aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the risk of gastric or esophageal adenocarcinomas.
Dr Abnet and colleagues from Maryland, USA examined the association between self-reported use of aspirin or non-aspirin NSAIDs in the earlier 12 months and gastric non-cardia, gastric cardia and esophageal adenocarcinomas in a prospective cohort of 311,115 patients followed for 7 years.
Hazard ratios and 95% confidence intervals come from Cox models adjusted for potential confounders.
|The odds ratio for aspirin use on cardia adenocarcinomas was 0.8|
|British Journal of Cancer|
The team found use of any aspirin or other non-steroidal anti-inflammatory drugs was associated with a significantly lower risk of gastric non-cardia adenocarcinoma.
Neither aspirin nor other non-steroidal anti-inflammatory drugs had a significant association with gastric cardia cancer.
The researchers found no significant association between using aspirin or other non-steroidal anti-inflammatory drugs and esophageal adenocarcinoma.
The summary odds ratio for aspirin use on non-cardia, cardia, and esophageal adenocarcinomas was 0.6, 0.8, and 0.6, respectively.”
The corresponding numbers for other non-steroidal anti-inflammatory drugs were 0.7, 0.8, and 0.65, respectively.
Dr Abnet’s team concluded, “In this analysis, aspirin use was inversely associated with both gastric and esophageal adenocarcinomas.”